<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03418571</url>
  </required_header>
  <id_info>
    <org_study_id>ALX0171-C203</org_study_id>
    <nct_id>NCT03418571</nct_id>
  </id_info>
  <brief_title>Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection</brief_title>
  <official_title>A Randomized, Double-blind, Multicenter, Multiple-dose Study of ALX-0171 Versus Placebo Along With Standard of Care in Japanese Infants and Young Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ablynx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ablynx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a randomized, double-blind, multicenter, Phase II study (NCT03418571) designed to
      support the selection of an optimal dose of inhaled ALX-0171 for further clinical
      development, taking ethnicity into consideration.

      Based on the results of the Phase IIb dose-ranging study ALX0171-C201 (RESPIRE), the Sponsor
      decided to discontinue ALX-0171 development in infants and to early terminate the
      ALX0171-C203 study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Four dose levels were planned to be evaluated in four consecutive cohorts consisting of
      Japanese infants and young children aged 28 days to &lt;2 years with a gestational age ≥33 weeks
      who were hospitalized for and diagnosed with respiratory syncytial virus (RSV) lower
      respiratory tract infection (LRTI):

        -  Dose level 1: target dose of 1.5 mg/kg

        -  Dose level 2: target dose of 3.0 mg/kg

        -  Dose level 3: target dose of 6.0 mg/kg

        -  Dose level 4: target dose of 9.0 mg/kg

      Each cohort was planned to consist of 15 subjects enrolled and randomly assigned to receive
      ALX-0171 or placebo, in an allocation ratio of 4:1 (N = 12 active versus N = 3 placebo per
      cohort).

      Due to early termination of the trial, only enrollment of Cohort 1 could be completed as
      planned. For Cohort 2, only 1 subject was screened but did not meet the eligibility criteria
      and was considered a screen failure. Therefore, data were not available for treatment groups
      ALX-0171 3.0 mg/kg, 6.0 mg/kg, and 9.0 mg/kg.

      Of note, in line with applicable guidelines, an Independent Data Monitoring Committee (IDMC)
      was assigned to monitor the study. Upon completing of Cohort 1, the IDMC reviewed the
      available unblinded safety data and unanimously recommended to continue the study with no
      changes to the protocol.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The Sponsor decided to discontinue ALX-0171 development (due to insufficient evidence of
    efficacy). As a result, the ALX0171-C203 study was early terminated.
  </why_stopped>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">October 24, 2018</completion_date>
  <primary_completion_date type="Actual">October 24, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of Inhaled ALX-0171 1.5 mg/kg as Measured by the Number of Subjects With at Least 1 Serious or Non-Serious Treatment-emergent Adverse Event (TEAE).</measure>
    <time_frame>From the subject's first study drug administration until completion of the subject's last visit, an average of 4 weeks</time_frame>
    <description>Number of subjects reported with at least 1 serious or non-serious TEAEs in the ALX-0171 1.5 mg/kg treatment group and placebo treatment group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of Inhaled ALX-0171 1.5 mg/kg as Measured by the Number of Serious and Non-serious TEAEs.</measure>
    <time_frame>From the subject's first study drug administration until completion of the subject's last visit, an average of 4 weeks</time_frame>
    <description>Number of serious and non-serious TEAEs reported in the ALX-0171 1.5 mg/kg treatment group and placebo treatment group.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Respiratory Syncytial Virus Lower Respiratory Tract Infection</condition>
  <arm_group>
    <arm_group_label>ALX-0171 1.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALX-0171 1.5 mg/kg</intervention_name>
    <description>ALX-0171 1.5 mg/kg was administered via a single inhalation once daily for 3 consecutive days.</description>
    <arm_group_label>ALX-0171 1.5 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo was administered via a single inhalation once daily for 3 consecutive days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion criteria:

          1. Subject was a Japanese male or female infant or young child aged 28 days to &lt;2 years
             with gestational age ≥33 weeks at screening.

          2. Subject was of Japanese descent, i.e., born in Japan to Japanese parents and had
             Japanese maternal and paternal grandparents.

          3. Subject weighed between ≥3.0 kg and &lt;15.0 kg at screening.

          4. Subject was otherwise healthy, but was hospitalized for and clinically diagnosed with
             RSV LRTI (bronchiolitis or broncho-pneumonia), i.e., showing typical clinical signs
             and symptoms such as tachypnea, wheezing, cough, crackles, use of accessory muscles
             and/or nasal flaring.

          5. Subject had a positive RSV diagnostic test within 4 days of screening.

          6. Subject was expected to have to stay in the hospital for at least 24 hours (according
             to the Investigator's judgment at screening).

          7. Symptoms likely related to RSV infection (i.e., the symptoms present needed to be
             probably linked to the current RSV infection according to Investigator's judgment) had
             appeared within 4 days of screening and were not yet improving at screening and
             randomization.

          8. Subject fulfilled at least two of the following RSV disease severity criteria at
             screening and randomization:

               -  Inadequate oral feeding that required feeding support (i.e., nasogastric tube or
                  i.v. line),

               -  Inadequate oxygen saturation defined as:

                    -  Peripheral capillary oxygen saturation (SpO2) &lt;95% on room air, or

                    -  Requiring oxygen supplementation to maintain adequate oxygen saturation with
                       documented pre-supplementation value &lt;95%

               -  Signs of respiratory distress defined as:

                    -  Respiratory rate ≥50 breaths per minute in infants up to 12 months of age,
                       and ≥40 breaths per minute in children above 12 months, and/ or

                    -  Moderate or marked respiratory muscle retractions

          9. Subject had normal psychomotor development.

        Others as defined in the protocol

        Main exclusion criteria:

          1. Subject was known to have significant comorbidities including:

               -  Genetic disorders (e.g., trisomy 21, cystic fibrosis),

               -  Hemodynamically significant congenital heart disease (e.g., needing corrective
                  therapy or inotropic support),

               -  Bronchopulmonary dysplasia,

               -  Any hereditary or acquired metabolic (bone) diseases,

               -  Hematologic or other malignancy.

          2. Subject was known to be human immunodeficiency virus (HIV)-positive. If the subject
             was &lt;6 months of age, known HIV-positivity of the mother was also exclusionary.

          3. Subject was known to be immunocompromised.

          4. Subject had or was suspected to have an active, clinically relevant concurrent
             infection (e.g., bacterial pneumonia, urinary tract infection). Concurrent acute
             otitis media was not exclusionary.

          5. Subject had significant oral and/or maxillofacial malformations which would have
             prevented proper positioning of the face mask.

          6. Subject received invasive mechanical ventilation or non-invasive respiratory support
             (i.e., continuous or bilevel positive airway pressure) in the 4 weeks prior to
             screening.

          7. During the current admission, subject was initially hospitalized in an Intensive Care
             Unit (ICU) setting and/or received invasive mechanical ventilation or non-invasive
             respiratory support (i.e., continuous or bilevel positive airway pressure).

          8. Subject was critically ill and/or was expected to require invasive mechanical
             ventilation, non-invasive respiratory support (i.e., continuous or bilevel positive
             airway pressure), or high-flow oxygen therapy (HFOT) at levels not enabling
             nebulization therapy according to the Investigator's judgment. High-flow oxygen, with
             a maximum flow of 2 L/kg/min, was permitted under the following conditions:

               -  used as Standard of Care outside ICU setting

               -  could be removed for study drug administration (Note: oxygen flow at 2 L/minute
                  could be provided through the nebulizer)

          9. Subject had received 1 or more doses of palivizumab or treatment or prophylaxis with
             any RSV antiviral compound (e.g., ribavirin, i.v. immunoglobulin, or any
             investigational drug or vaccine for RSV [including subject's mother who had been
             vaccinated against RSV]) at any time prior to screening.

         10. Subject was required to continue or start systemic corticosteroid therapy. Subject on
             a maintenance therapy of inhaled corticosteroids could continue this treatment at the
             usual dose. Topical corticosteroids for skin disorders were permitted.

         11. Subject had clinically meaningful abnormalities on a 12-lead electrocardiogram (ECG),
             which according to the Investigor's judgement did not allow participation of the
             subject in the study. A 12-lead ECG performed within 4 days of screening was
             acceptable. If not available, the 12-lead ECG could be performed at the time of
             screening.

        Others as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Ablynx NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Aoi-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Asahikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Fuchu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Fukuyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Funabashi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Isesaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Koga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Kurashiki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Kurume-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Meguro-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Minami-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Nagano-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Saitama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Shimotsuke-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Takatsuki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Toshima-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Toyohira</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Ueda</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Wako</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Yachiyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 1</name>
      <address>
        <city>Yokosuka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 2</name>
      <address>
        <city>Yokosuka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Ōmura</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 26, 2018</study_first_submitted>
  <study_first_submitted_qc>January 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <results_first_submitted>May 2, 2019</results_first_submitted>
  <results_first_submitted_qc>May 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 15, 2019</results_first_posted>
  <last_update_submitted>July 17, 2019</last_update_submitted>
  <last_update_submitted_qc>July 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT03418571/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT03418571/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sixteen subjects were screened for Cohort 1. Of these, 15 subjects were randomized. There was 1 screen failure due to consent withdrawal.
For Cohort 2, 1 subject was screened but considered a screen failure (consent withdrawal).
Consent was obtained from the first subject on 1 March 2018; last subject completed the final visit on 19 October 2018</recruitment_details>
      <pre_assignment_details>All randomized subjects received at least 1 administration of study drug and were included in the Safety Population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ALX-0171 1.5 mg/kg</title>
          <description>Single inhalation of ALX-0171 1.5 mg/kg once daily for 3 consecutive days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Single inhalation of placebo once daily for 3 consecutive days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Consent withdrawn by legal guardian</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ALX-0171 1.5 mg/kg</title>
          <description>Single inhalation of ALX-0171 1.5 mg/kg once daily for 3 consecutive days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Single inhalation of placebo once daily for 3 consecutive days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.4" spread="4.65"/>
                    <measurement group_id="B2" value="3.5" spread="3.04"/>
                    <measurement group_id="B3" value="6.6" spread="4.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Inhaled ALX-0171 1.5 mg/kg as Measured by the Number of Subjects With at Least 1 Serious or Non-Serious Treatment-emergent Adverse Event (TEAE).</title>
        <description>Number of subjects reported with at least 1 serious or non-serious TEAEs in the ALX-0171 1.5 mg/kg treatment group and placebo treatment group.</description>
        <time_frame>From the subject's first study drug administration until completion of the subject's last visit, an average of 4 weeks</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0171 1.5 mg/kg</title>
            <description>Single inhalation of ALX-0171 1.5 mg/kg once daily for 3 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single inhalation of placebo once daily for 3 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Inhaled ALX-0171 1.5 mg/kg as Measured by the Number of Subjects With at Least 1 Serious or Non-Serious Treatment-emergent Adverse Event (TEAE).</title>
          <description>Number of subjects reported with at least 1 serious or non-serious TEAEs in the ALX-0171 1.5 mg/kg treatment group and placebo treatment group.</description>
          <population>Safety Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one non-serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Inhaled ALX-0171 1.5 mg/kg as Measured by the Number of Serious and Non-serious TEAEs.</title>
        <description>Number of serious and non-serious TEAEs reported in the ALX-0171 1.5 mg/kg treatment group and placebo treatment group.</description>
        <time_frame>From the subject's first study drug administration until completion of the subject's last visit, an average of 4 weeks</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0171 1.5 mg/kg</title>
            <description>Single inhalation of ALX-0171 1.5 mg/kg once daily for 3 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single inhalation of placebo once daily for 3 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Inhaled ALX-0171 1.5 mg/kg as Measured by the Number of Serious and Non-serious TEAEs.</title>
          <description>Number of serious and non-serious TEAEs reported in the ALX-0171 1.5 mg/kg treatment group and placebo treatment group.</description>
          <population>Safety Population</population>
          <units>TEAE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the subject's first study drug administration until the subject's study completion/discontinuation date, an average of 4 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ALX-0171 1.5 mg/kg</title>
          <description>Single inhalation of ALX-0171 1.5 mg/kg once daily for 3 consecutive days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Single inhalation of placebo once daily for 3 consecutive days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia hemophilus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of any results from this study will be according to the principles of the Declaration of Helsinki, in particular point 30, and will require prior review and written agreement of the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Based on the results of the Phase IIb study ALX0171-C201 (RESPIRE), the Sponsor decided to discontinue ALX-0171 development in infants and to early terminate the ALX0171-C203 study. Therefore, no data are available for the higher dose groups.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Monitor</name_or_title>
      <organization>Ablynx NV</organization>
      <phone>+32 9 262 00 00</phone>
      <email>clinicaltrials@ablynx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

